Ruth March
AstraZeneca (United Kingdom)(GB)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, CRISPR and Genetic Engineering, BRCA gene mutations in cancer, Genetic Associations and Epidemiology, Genomics and Rare Diseases
Most-Cited Works
- → Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework(2014)1,323 cited
- → Diagnostic Utility of Exome Sequencing for Kidney Disease(2018)736 cited
- → Rare variant contribution to human disease in 281,104 UK Biobank exomes(2021)571 cited
- → Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment(2005)476 cited
- → Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank(2021)423 cited
- → Impact of a five-dimensional framework on R&D productivity at AstraZeneca(2018)413 cited
- → Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis